About
A deep-seated faith in the transformative capacities of science and art alike, and in their shared role in addressing the most pressing challenges our world faces.
My approach to business and life is galvanized by a relentless “immigrant mentality”, embodying an unfaltering work ethic, matched with an ethical compass that harmonizes with an audacious streak of creativity. I am a believer in the emancipating powers of imagination, which affords a temporary pass to interrogate entrenched perspectives of the world, fueling the conversion of simple observations into unprecedented discoveries.
Traversing executive strategy, venture capital, and technology innovation, my professional repertoire serves as a bedrock to engage with organizations and founders alike, helping them navigate the anfractuous terrain of exponential technology and uncover fresh avenues for growth. At Link Ventures, I helped establish and launch the Link-XPV Fund, a nearly $250M Venture Fund investing primarily in enterprise AI out of the Boston ecosystem alongside Peter Diamandis and Dave Blundin. Before that, I served as the “Strike Force” Entrepreneur-in-Residence alongside futurist Dr. Peter H. Diamandis, operating as strategic counsel, board observer, and intellectual collaborator.
Working at the confluence of AI and other exponential technologies, a key focus area is to pioneer developments in the arena of healthy aging and human longevity. As I find myself at this remarkable nexus of technologies, my ambition is to significantly influence the global health trajectory, making a substantial, enduring impact on people worldwide.
Three key focus areas,one direction.
Longevity Biosciences
Therapeutics, diagnostics, and platforms extending human healthspan, from senolytics and epigenetic reprogramming to novel biomarker discovery.
Applied AI
Infrastructure and applications where machine intelligence compounds domain-specific value.
Data & Exponential Tech
The pipes, protocols, and platforms that make the first two possible.
Backing the pre-eminent ecosystem and platform for synthetic and programmable biology.
Investing.Advising.
Merge LabsNeurotechBrain-computer interfaces and neural engineering for next-generation human-machine interaction.
02
Science Corp.Neurotech / LongevityBuilding technologies to understand and interface with the brain to restore and augment human capability.
03
NewLimitLongevity / EpigeneticsEpigenetic reprogramming to radically extend human healthspan.
04
General ControlBiotech / EpigeneticsDurable, reversible multi-gene epigenetic therapies to combat age-related diseases and advance healthier aging.
05
Lila SciencesAI / ScienceBuilding AI-powered science factories across therapeutics, physical sciences, and beyond, accelerating discovery at industrial scale.
06
OrnnFintech / AI InfrastructureThe first U.S.-regulated derivatives exchange for GPU compute. Futures and swaps to hedge AI costs and manage capacity risk.
07
Valar AtomicsEnergy / NuclearAdvanced nuclear energy solutions for a clean energy future.
08
AndurilDefense TechAutonomous defense systems and AI-powered national security infrastructure.
09
xAIAI / Foundation ModelsBuilding frontier AI to understand the universe.
10
SpaceXAerospaceMaking humanity multi-planetary through reusable rocket technology.
11
nudeHealth / ConsumerPremium health-forward consumer brand based in Miami.
CapableLongevity / Peptide TherapeuticsVertically integrated, AI-driven biology developing next-generation peptide therapeutics to expand human capability, beginning with sleep.
02
Haut.AIAI / Skin ScienceAI-powered skin analysis and longevity biomarker platform.
03
ImmunisLongevity / ImmunologyRestoring immune function to combat age-related decline.
04.png){kind=logo}
OpenWaterNeurotech / ImagingNon-invasive brain imaging and therapeutic technology.
05
Alsym EnergyEnergy / BatteriesNon-lithium, non-cobalt battery technology for global energy access.
06
Variant3DDeep TechAdvanced 3D printing and manufacturing innovation.
07
Applied AIAI / EnterpriseEnterprise AI solutions driving operational transformation.
08
CatalanAI / Dynamic PricingAI-powered dynamic pricing and revenue optimization.
From observation,to narrative, toculture-defining companies.
- Backing the pre-eminent ecosystem and platform for synthetic and programmable biology, at the confluence of longevity biosciences, AI, and data.
- Co-curator of the Abundance Longevity Trip with Peter Diamandis, 2022–present, now in its fourth year.
- Founding team member of the nearly $250M early-stage fund, primarily enterprise AI, rooted in the Boston ecosystem; helped establish and launch it from Day 1 alongside Peter Diamandis and Dave Blundin.
- The accompanying venture studio drew roughly 75% of investments from Harvard and MIT.
- Early-stage investments included Mercor, Blitzy, and Ornn.
- Platform reach through the Future Investment Initiative (FII), World Economic Forum (WEF), Abundance Summit, and Moonshots Podcast.
- Primary thought partner and strategic counsel; board observer and intellectual collaborator across health and longevity.
- XPRIZE Healthspan: worked alongside Peter Diamandis from the earliest days of the competition, helping shape the initial prize skeleton and structure, leading the search that identified its Executive Director, and helping raise the $157M that made it the largest XPRIZE in the foundation’s history.
- Abundance Longevity Trip: began co-curating the program in 2022 during this role and continues to co-curate it today, now in his fourth year. A highly curated gathering of longevity scientists, founders, and investors, with the scientists and founders selectively screened, capped at roughly 80 members with 50+ faculty, including Nobel laureate Shinya Yamanaka, Matt Walker, and David Sinclair, and widely regarded as among the most exclusive healthspan experiences in the world.
- Personally reviewed and evaluated over 400 life sciences companies advancing human healthspan each year, a sustained volume of diligence that has produced a rare, sharply calibrated pattern recognition across the field: the ability to distinguish signal from narrative, and durable biology from a compelling deck, early.
- Supported the early development of Fountain Life, the diagnostics and therapeutics clinic network co-founded by Diamandis and Tony Robbins.
- Doctoral training in the Tumor Biology program at Georgetown University Medical Center, working at the intersection of cellular biology, biochemistry, and translational science.
- Research centered on women’s health: estrogen receptor–positive breast cancer, the most common form of the disease, and the question of why roughly a third of these tumors fail to respond to, or become resistant to, hormonal therapy.
- In the laboratory of Dr. Mary Beth Martin, studied metalloestrogens: how calcium and the environmental metal cadmium activate estrogen receptor α, mimic estrogen, and drive hormone-independent, endocrine-resistant disease, linking environmental exposure to breast cancer biology.
- First author on work showing that cadmium activates wild-type ERα and further amplifies the constitutively active ESR1 mutants Y537S and D538G associated with acquired resistance to endocrine therapy, and that calcium channel blockers and chelators suppress the growth of cells carrying them, pointing toward repurposable, clinically available interventions for resistant breast cancer.
- Founder & President of the Georgetown Graduate Consulting Club, which grew into the largest graduate student organization on campus and was recognized with Georgetown’s Outstanding Graduate Student Organization Award.
“The conservation of health is the principal good and the foundation of all other goods.”René Descartes
Get in touch
Contact
For founders, partnerships, or speaking engagements.